From: FierceHealthcare
The Trump administration is considering a proposal to overhaul safe harbor protections for pharmaceutical company rebates, a plan that could lead to a significant shift in how drug prices are determined.
The Office of Management and Budget is reviewing a proposed rule from the Department of Health and Human Services on the matter. Details on how exactly HHS wants to rethink safe harbors are scant, as the rule will not be released publicly until OMB signs off on it.